This study aimed to identify the optimal dose of the endothelin-1 receptor antagonist atrasentan with maximal albuminuria reduction and minimal signs of sodium retention, as manifested by increase in bodyweight. Data from the RADAR-JAPAN studies were used, evaluating the effect of 0.75 or 1.25 mg/d of atrasentan in 161 patients with type 2 diabetes and kidney disease.
2 | METHODS
| Clinical trial design and patient population
Data from 161 participants in the RADAR (NCT01356849) and JAPAN (NCT01424319) trials were used. The RADAR and JAPAN trials assessed the effect of atrasentan on albuminuria reduction. The design and primary results of both trials were previously published. 5 To be eligible, participants were required to have a urinary albuminto-creatinine ratio (UACR) within 300 to 3500 mg/g and an estimated glomerular filtration rate (eGFR) of 30 to 75 mL/min/1.73 m 2 . As per protocol, all participants received the maximum tolerated labeled daily dose of a renin-angiotensin-aldosterone-system (RAAS) inhibitor.
Patients were randomly allocated to 12 weeks of treatment with atrasentan at doses of 0.75 or 1.25 mg/d, or a placebo using a doubleblind design. The primary endpoint of the trial was the change in UACR over time.
Three consecutive first-void urine specimens were collected at baseline and every 2 weeks thereafter to determine urinary albumin and creatinine concentrations. Blood samples were sparsely collected to determine plasma atrasentan exposure. In line with previous reports of this trial, changes in bodyweight were used as proxy for sodium retention. Analyses focused on changes in sodium retention after 2 weeks of atrasentan therapy in order to maximise detection of atrasentan on sodium retention.
| Pharmacokinetic and pharmacodynamic analyses
The population pharmacokinetic model was previously published. Regulatory agencies have developed rigorous guidelines on how to use dose-response data to support dose selection and drug registration. 7, 8 Despite these rigorous guidelines, dose-finding studies to determine the optimal therapeutic dose are hampered by various A further problem in determining the optimal therapeutic dose is that its selection is based on an inadequate balance between efficacy and safety. Traditionally, dose finding is based on the drug's efficacy in modifying a single risk factor that the drug is targeting-for example, blood pressure for an antihypertensive drug. The safety is mainly established from a fixed set of parameters. However, many drugs have effects on other parameters (off-target effects), which may also be risk factors that contribute to clinical outcomes, either in a positive or a negative way. The sodium retention effect of ERAs is one such offtarget effect that contributes to clinical outcomes in a negative way.
Therefore, dose selection should be based on the balance of drug effects on multiple parameters, both on those that contribute to protection and those that induce harm.
These problems in selecting the optimal therapeutic dose for an ERA are illustrated by the ERA avosentan. A phase III trial (ASCEND)
with avosentan was terminated early because of an increased incidence of congestive heart failure probably caused by the sodiumretaining effects. 10 In hindsight, the increased sodium retention and congestive heart failure could have been expected, because the high doses of 25 and 50 mg used in the phase III trial were associated with significant sodium retention and peripheral edema in an earlier dosefinding trial. 11 Despite the high incidence of edema, the 25 and 50 mg doses were selected for the phase III outcome trial. This highlights the importance of careful dose selection when balancing maximal albuminuria reduction and minimal sodium retention.
Additionally, the high doses used in the ASCEND trial are not the only explanation for the increased edema and heart failure, but also the difference in populations studied in the phase III outcome trial and the dose-finding study. In the phase III trial, patients with overt diabetic nephropathy were enrolled; they had a mean eGFR of 33 mL/ min/1.73 m 2 . 3 These patients are prone to sodium retention. However, in the dose-finding study, patients who are less prone to sodium retention, with an estimated creatinine clearance of~80 mL/min, were enrolled. 12 This finding also highlights the importance of strictly monitoring patients with diabetes and impaired kidney function for signs of sodium retention.
For the development of the ERA atrasentan, the main inclusion and exclusion criteria for the phase II and III trials were kept similar, and the sodium-retaining effects of atrasentan were carefully analysed during the dose selection process. However, the sample size of the atrasentan phase II dose-finding study was small, thus limiting the accuracy and precision of the dose-finding analyses.
In conclusion, the exposure-response analysis showed that 0.75 mg/d of atrasentan as an adjunct to RAAS inhibition is the optimal dose for renal protection with maximal albuminuria reduction while minimising sodium retention. 
